P01116 (RASK_HUMAN) Homo sapiens (Human)
GTPase KRas UniProtKBInterProSTRINGInteractive Modelling
Available Structures
361 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| NMR data-driven model of GTPase KRas-GDP tethered to a lipid-bilayer nanodisc |
Heteromer P02647; | 97.01 | 64×PCW; 16×17F; 1×GDP; 1×MG; | |||
| NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state A) |
Heteromer P02647; P04049; | 97.01 | 64×PCW; 16×17F; 1×GNP; 1×MG; 2×ZN; | |||
| NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state B) |
Heteromer P02647; P04049; | 97.01 | 64×PCW; 16×17F; 1×GNP; 1×MG; 2×ZN; | |||
| NMR data-driven model of GTPase KRas-GNP:ARafRBD complex tethered to a lipid-bilayer nanodisc |
Heteromer P02647; P10398; | 97.01 | 64×PCW; 16×17F; 1×GNP; 1×MG; | |||
| NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc |
Heteromer P02647; | 96.41 | 64×PCW; 16×17F; 1×GNP; 1×MG; 1×EWS; | |||
| NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc |
Heteromer P02647; | 96.41 | 64×PCW; 16×17F; 1×GNP; 1×MG; 1×EWS; | |||
| NMR data-driven model of GTPase KRas-GNP tethered to a lipid-bilayer nanodisc |
Heteromer P02647; | 97.01 | 64×PCW; 16×17F; 1×GNP; 1×MG; | |||
| NMR data-driven model of GTPase KRas-GMPPNP tethered to a nanodisc (E3 state) |
Heteromer P02647; | 96.41 | 64×PCW; 16×17F; 1×GNP; 1×MG; | |||
| Crystal structure of farnesylated and methylated kras4b in complex with PDE-delta (crystal form II … |
Heteromer O43924; | 96.99 | 1×FAR; 1×GDP; 1×EDO; | |||
| Crystal structure of full-length farnesylated and methylated KRAS4b in complex with PDE-delta (crys… |
Heteromer O43924; | 96.81 | 1×FAR; 1×GDP; 1×EDO; | |||
| Crystal structure of the high affinity KRas mutant PDE6D complex |
Heteromer O43924; | 96.86 | 2×GDP; 2×FAR; 3×SO4; 5×EDO; | |||
| NMR-driven structure of KRAS4B-GTP homodimer on a lipid bilayer nanodisc |
Heteromer P02647; | 96.39 | 64×PCW; 16×17F; 2×GSP; 2×MG; | |||
| NMR-driven structure of the KRAS4B-G12D "alpha-alpha" dimer on a lipid bilayer nanodisc |
Heteromer P02647; | 96.39 | 2×GSP; 2×MG; 128×7Q9; 32×17F; | |||
| NMR-driven structure of the KRAS4B-G12D "alpha-beta" dimer on a lipid bilayer nanodisc |
Heteromer P02647; | 96.39 | 2×GSP; 2×MG; 128×7Q9; 32×17F; | |||
| NMR-driven structure of KRAS4B-GDP homodimer on a lipid bilayer nanodisc |
Heteromer P02647; | 96.32 | 64×PCW; 16×17F; 2×GDP; 2×MG; | |||
| Crystal structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD) |
Heteromer P04049; | 100 | 1×MG; 1×GNP; | |||
| KRAS full-length G12V in complex with RGL1 Ras association domain |
Heteromer Q9NZL6; | 95.81 | 2×MG; 2×GSP; 2×PO4; | |||
| KRAS full length wild-type in complex with RGL1 Ras association domain |
Heteromer Q9NZL6; | 96.41 | 1×MG; 1×GSP; | |||
| Crystal Structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD-CRD) |
Heteromer P04049; | 100 | 1×GNP; 1×MG; 2×ZN; | |||
| Crystal structure of human K-Ras G12D Mutant in complex with GDP and Cyclic Inhibitory Peptide |
Heteromer | 95.86 | 1×GDP; 1×EDO; | |||
| Tricomplex of RMC-7977, KRAS G12C, and CypA |
Heteromer P62937; | 95.86 | 1×GNP; 1×MG; 1×ZNI; | |||
| Tri-complex of Compound-12, KRAS G12C, and CypA |
Heteromer P62937; | 94.08 | 1×GNP; 1×A1AOL; 1×CL; | |||
| Tricomplex of Compound-1, KRAS G12C, and CypA |
Heteromer P62937; | 94.08 | 1×GNP; 1×MG; 1×YV6; | |||
| Tricomplex of RMC-7977, KRAS G12A, and CypA |
Heteromer P62937; | 95.86 | 1×GNP; 1×MG; 1×ZNI; | |||
| Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor LUNA18 and KA30L Fab |
Heteromer | 96.39 | 1×GDP; 1×MG; | |||
| Tricomplex of RMC-4998, KRAS G12C, and CypA |
Heteromer P62937; | 95.86 | 1×GNP; 1×MG; 1×CL; 1×YV2; | |||
| Tricomplex of RMC-7977, KRAS WT, and CypA |
Heteromer P62937; | 96.45 | 1×GNP; 1×MG; 1×ZNI; | |||
| Tricomplex of RMC-7977, KRAS G12R, and CypA |
Heteromer P62937; | 95.86 | 1×GNP; 1×MG; 1×ZNI; | |||
| Crystal structure of GMPPNP bound KRAS G12D in complex with CYPA and RMC-7977 |
Heteromer P62937; | 95.86 | 2×GNP; 2×MG; 2×ZNI; | |||
| Crystal structure of KRAS G12S in a transition state mimetic complex with CYPA and RMC-7977 |
Heteromer P62937; | 95.86 | 2×ZNI; 2×AF3; 2×MG; 2×GDP; | |||
| Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cys… |
Heteromer P04049; | 95.86 | 1×GNP; 1×MG; 2×SO4; 5×CL; 3×ZN; | |||
| Crystal structure of G13D-KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neurofibr… |
Heteromer P21359; | 95.86 | 1×GNP; 1×MG; 2×CL; 3×MES; | |||
| Crystal structure of GMPPNP bound KRAS G12C in complex with CYPA and RMC-7977 |
Heteromer P62937; | 95.86 | 2×GNP; 2×MG; 2×ZNI; | |||
| Crystal structure of Kas G12C in complex with 2H11 CLAMP |
Heteromer | 94.08 | 1×GDP; 1×MG; 3×CAC; 1×EDO; | |||
| RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT … |
Heteromer Q07889; | 93.49 | 1×GOL; 2×BPW; | |||
| Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment scr… |
Heteromer Q07889; | 93.49 | 1×GOL; 1×BQ5; | |||
| Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment screening hit … |
Heteromer Q07889; | 93.49 | 1×GOL; 1×BQ2; 1×DMS; | |||
| Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) |
Heteromer Q07889; | 93.49 | 1×GOL; | |||
| Crystal structure of wild-type KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neur… |
Heteromer P21359; | 96.45 | 2×GOL; 1×GNP; 1×MG; 1×IMD; 1×CL; | |||
| Tricomplex of RMC-7977, KRAS G12S, and CypA |
Heteromer P62937; | 95.83 | 1×GNP; 1×MG; 1×ZNI; | |||
| Tri-complex of Compound-3, KRAS G12V, and CypA |
Heteromer P62937; | 95.83 | 1×GNP; 1×MG; 1×A1AOH; | |||
| Crystal structure of SOS1-KRasG12V-Nanobody14 |
Heteromer Q07889; | 95.76 | ||||
| Crystal structure of KRAS G12A in a transition state mimetic complex with CYPA and RMC-7977 |
Heteromer P62937; | 95.83 | 2×ZNI; 2×GDP; 2×AF3; 2×MG; | |||
| Crystal Structure of KRAS-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine… |
Heteromer P04049; | 95.83 | 1×GNP; 1×MG; 3×ZN; 2×GOL; 1×CL; | |||
| RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT … |
Heteromer Q07889; | 93.45 | 1×GOL; 1×BOQ; | |||
| Monobody 12D5 bound to KRAS(G12D) |
Heteromer | 93.79 | 1×MG; 1×GDP; 2×GLC; | |||
| Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cys… |
Heteromer P04049; | 96.39 | 1×GNP; 1×MG; 3×CL; 2×GOL; 1×IPA; 2×ZN; | |||
| Crystal structure of Q61L KRAS(GMPPNP)-NF1(GRD)-SPRED1(EVH1) complex |
Heteromer P21359; Q7Z699; | 95.83 | 4×FMT; 1×GNP; 1×MG; 1×ZN; | |||
| Crystal Structure of KRAS-Q61R (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine… |
Heteromer P04049; | 95.83 | 1×GNP; 1×MG; 3×ZN; 2×GOL; | |||
| Crystal structure of KRAS(GMPPNP)-NF1(GRD)-SPRED1 complex |
Heteromer P21359; Q7Z699; | 96.43 | 4×FMT; 1×GNP; 1×MG; 1×ZN; | |||
| Crystal Structure of KRAS-G12V (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine… |
Heteromer P04049; | 95.24 | 1×GNP; 4×GOL; 1×MG; 2×CL; 2×ZN; | |||
| Structure of a ternary KRas(G13D)-SOS complex |
Heteromer Q07889; | 95.83 | 1×GNP; 1×MG; | |||
| KRAS G13C complex with GDP imaged on a cryo-EM imaging scaffold |
Heteromer | 94.05 | 1×GDP; 1×MG; | |||
| KRAS G12C complex with GDP and AMG 510 imaged on a cryo-EM imaging scaffold |
Heteromer | 95.83 | 1×MG; 1×GDP; 1×MOV; | |||
| Crystal Structure of wild-type KRAS4b (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RA… |
Heteromer P04049; | 97.01 | 1×MG; 1×GNP; 3×CL; 2×EDO; 1×MPD; | |||
| Tricomplex of RMC-7977, KRAS G12V, and CypA |
Heteromer P62937; | 96.41 | 1×GNP; 1×MG; 1×ZNI; | |||
| Tricomplex of RMC-6236, KRAS G12D, and CypA |
Heteromer P62937; | 94.61 | 1×GNP; 1×MG; 1×A1AHB; | |||
| Affimer K69 - KRAS protein complex |
Heteromer | 97.01 | 1×GDP; 1×MG; | |||
| Tricomplex of RMC-7977, KRAS G12D, and CypA |
Heteromer P62937; | 94.61 | 1×GNP; 1×MG; 1×ZNI; | |||
| KRas G12C in complex with G-2897 |
Heteromer | 96.41 | 1×Z07; 1×GDP; 1×MG; 2×ACT; 4×CAD; 4×P15; 4×EDO; 1×DMS; | |||
| Crystal Structure of KRAS4b-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CR… |
Heteromer P04049; | 96.41 | 1×GNP; 1×MG; | |||
| Crystal structure of KRAS G12C in a transition state mimetic complex with CYPA and RMC-7977 |
Heteromer P62937; | 96.41 | 2×ZNI; 2×AF3; 2×GDP; 2×MG; | |||
| KRAS G12V and H-REV107 peptide complex |
Heteromer P53816; | 96.41 | 1×GDP; 1×MG; | |||
| Crystal Structure of KRAS4b (GMPPNP-bound) in complex with the RBD-PH domains of SIN1 |
Heteromer Q9BPZ7; | 96.41 | 1×MG; 1×GNP; | |||
| Monobody 12D1 bound to KRAS(G12D) |
Heteromer | 94.61 | 1×GDP; 1×MG; 1×NA; | |||
| Heterotetramer of K-Ras4B(G12V) and Rgl2(RBD) |
Heteromer O15211; | 96.41 | 2×MG; 2×GNP; | |||
| Cryo-EM structure of a RAS/RAF complex (state 2) |
Heteromer P15056; Q02750; V9P4T4; | 97.01 | 2×AGS; 2×ZN; 2×MG; 1×LCJ; 1×GNP; | |||
| Cryo-EM structure of a RAS/RAF complex (state 1) |
Heteromer P15056; Q02750; V9P4T4; | 97.01 | 2×AGS; 2×ZN; 2×MG; 1×LCJ; 1×GNP; | |||
| CryoEM structure of GNE-1952-alkylated KRAS G12C in complex with engineered conformationally rigid … |
Heteromer | 94.61 | 1×A1AAW; 1×GDP; 1×MG; | |||
| Crystal Structure of KRas4A(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1 |
Heteromer Q9BPZ7; | 100 | 1×MG; 1×GNP; | |||
| Human KRAS in complex with darpin K19 |
Heteromer | 96.88 | 4×SO4; | |||
| KRasG12C ligand complex |
Heteromer A0A1S2ZE25; | 95.18 | 2×MG; 2×GDP; 2×MKW; | |||
| KRas G12V, bound to GppNHp and miniprotein 225-15a/b |
Heteromer | 96.86 | 1×GNP; 1×MG; 1×PG4; 2×SO4; | |||
| Crystal structure of KRasG12V-Nanobody84 |
Heteromer | 96.86 | 1×MG; 1×GDP; | |||
| Affimer K6 - KRAS protein complex |
Heteromer | 97.53 | 1×GDP; 1×MG; | |||
| Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP |
Heteromer | 96.39 | 1×MKZ; 1×GDP; 1×MG; 4×GOL; 3×EDO; 1×SO4; | |||
| Affimer K3 - KRAS protein complex |
Heteromer | 96.99 | 1×GDP; 1×MG; | |||
| KRas G12V, bound to GDP and miniprotein 225-11(A30R) |
Heteromer | 96.88 | 1×GDP; 1×MG; 4×CA; | |||
| K-RasG12D(GNP)/R11.1.6 complex |
Heteromer | 96.99 | 1×GNP; 1×MG; 2×CL; 1×CA; 1×CD; | |||
| Human KRAS in complex with darpin K13 |
Heteromer | 96.99 | 1×GDP; 2×SO4; | |||
| Wild-type K-Ras(GNP)/R11.1.6 complex |
Heteromer | 97.59 | 1×GNP; 3×CA; 4×CD; 3×CL; 1×MG; 3×CO; | |||
| Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB |
Heteromer P40337; Q15369; Q15370; | 95.18 | 1×X53; 1×GDP; 1×MG; | |||
| Crystal Structure of KRAS4b-Q61R (GMPPNP-bound) in complex with the RAS-binding domain (RBD) of SIN1 |
Heteromer Q9BPZ7; | 96.99 | 1×GNP; 1×MG; | |||
| KRas G12V/D38P, bound to GppNHp and miniprotein 225-11 |
Heteromer | 96.32 | 1×GNP; 4×CA; 1×MG; | |||
| KRas G12V, bound to GDP and miniprotein 225-11 |
Heteromer | 96.73 | 1×MG; 1×GDP; 2×CA; | |||
| Crystal structure of human RAS in complex with darpin K27 |
Heteromer | 97.58 | 1×GDP; 1×MG; | |||
| Human KRAS in complex with darpin K27 |
Heteromer | 97.58 | 1×GDP; 1×MG; | |||
| KRAS G12V complex with GDP imaged on a cryo-EM imaging scaffold |
Heteromer | 97.58 | 1×GDP; 1×MG; | |||
| KRAS G12C complex with GDP imaged on a cryo-EM imaging scaffold |
Heteromer | 97.58 | 1×GDP; 1×MG; | |||
| KRas G12V, bound to GppNHp and miniprotein 225-11(A30R) |
Heteromer | 98.04 | 1×GNP; 2×MG; 1×SO4; | |||
| Crystal structure of human RAS in complex with darpin K55 |
Heteromer | 98.17 | 1×MG; 1×GSP; 2×SO4; | |||
| Human KRAS in complex with darpin K27 |
Heteromer | 98.17 | 1×MG; 1×GSP; 2×SO4; | |||
| Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB |
Heteromer P40337; Q15369; Q15370; | 97.42 | 1×GDP; 1×X4R; 1×MG; | |||
| Crystal Structure of ligand ACBI3 in complex with KRAS G12D C118S GDP and pVHL:ElonginC:ElonginB co… |
Heteromer P40337; Q15369; Q15370; | 96.23 | 1×WYL; 1×GDP; 1×MG; | |||
| Crystal structure of SOS1-KRasG12V-Nanobody22-Nanobody75 |
Heteromer Q07889; | 98.11 | ||||
| PROTAC-mediated complex of KRAS with VHL/Elongin-B/Elongin-C/Cullin-2/Rbx1 |
Heteromer P40337; P62877; Q13617; Q15369; Q15370; | 97.56 | 2×ZN; 1×GDP; 1×WYL; | |||
| Structure of HLA-A2:01 with peptide MM96 |
Heteromer A0A140T913; P61769; | 90.0 | 4×GOL; 1×SO4; 2×NA; | |||
| Crystal structure of HLA-C05 in complex with a tumor mut10m peptide |
Heteromer P10321; P61769; | 90.0 | ||||
| Crystal structure of HLA-C08 in complex with a tumor mut10m peptide |
Heteromer C1K0Y1; P61769; | 90.0 | ||||
| HLA-A*03:01 with WT KRAS-10mer |
Heteromer P04439; P61769; | 100 | 1×GOL; | |||
| Structure of KRAS WT(7-16)-HLA-A*03:01 |
Heteromer P04439; P61769; | 100 | 13×SO4; 1×PEG; | |||
| G12V-TCR complex with HLA-A3 |
Heteromer P04439; P61769; | 90.0 | ||||
| Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2 |
Heteromer P04439; P61769; | 90.0 | ||||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer A0A3G8GE10; P61769; | 90.0 | 1×MOV; | |||
| Structure of the P1B7 antibody bound to the Sotorasib-modified KRas G12C peptide presented by the A… |
Heteromer P04439; P61769; | 90.0 | 1×MOV; | |||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P04439; P61769; | 90.0 | 1×MOV; | |||
| Structure of HLA-A2:01 with peptide MM90 |
Heteromer A0A140T913; P61769; | 88.89 | 6×GOL; 5×NA; | |||
| Crystal structure of HLA-C08 in complex with a tumor mut9m peptide |
Heteromer C1K0Y1; P61769; | 88.89 | ||||
| Crystal structure of TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (VVGAVGVGK) |
Heteromer A0A583ZB34; P01849; P61769; Q5R1I3; | 88.89 | ||||
| Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVGAGGVGK) |
Heteromer P61769; U5YJJ6; | 100 | ||||
| Crystal structure of affinity enhanced TCR in complex with HLA-A*11:01 bound to KRAS-G12V peptide (… |
Heteromer A0A583ZB34; P01849; P61769; Q5R1I3; | 88.89 | ||||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) |
Heteromer P61769; U5YJJ6; | 88.89 | ||||
| Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) |
Heteromer P61769; U5YJJ6; | 88.89 | ||||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P04439; P61769; | 88.89 | 1×MOV; | |||
| Structure of HLA-A2:01 with peptide MM92 |
Heteromer A0A140T913; P61769; | 75.0 | 3×GOL; 6×NA; 1×SO4; | |||
| Structure of HLA-A2:01 with peptide MM91 |
Heteromer A0A140T913; P61769; | 75.0 | 3×GOL; 4×NA; | |||
| CO-CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A K-RAS4B PEPTIDE SUBSTRATE … |
Heteromer Q02293; Q04631; | 80.0 | 1×ZN; 4×ACT; 1×FII; | |||
| PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A FARNESYLATED K-RAS4B PEPTIDE PRODUCT |
Heteromer Q02293; Q04631; | 80.0 | 1×ZN; 2×ACY; 1×FAR; | |||
| PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH FARNESYLATED K-RAS4B PEPTIDE PRODUCT AND FARNESYL DIPHOS… |
Heteromer Q02293; Q04631; | 80.0 | 1×ZN; 1×FPP; 1×ACY; 1×FAR; | |||
| Protein Geranylgeranyltransferase type-I Complexed with a GGPP Analog and a KKKSKTKCVIL Peptide |
Heteromer P53610; Q04631; | 60.0 | 1×ZN; 1×MGM; | |||
| Protein Geranylgeranyltransferase type-I Complexed with a Geranylgeranylated KKKSKTKCVIL Peptide Pr… |
Heteromer P53610; Q04631; | 60.0 | 1×MES; 1×ZN; 1×SO4; 1×GER; | |||
| Zinc-depleted FTase complexed with K-RAS4B peptide substrate and FPP analog. |
Heteromer Q02293; Q04631; | 80.0 | 1×ACT; 1×FII; | |||
| Protein Geranylgeranyltransferase type-I Complexed with GGPP and a Geranylgeranylated KKKSKTKCVIL P… |
Heteromer P53610; Q04631; | 50.0 | 1×ZN; 1×CL; 1×GRG; 1×GER; | |||
| Protein Geranylgeranyltransferase type-I Complexed with Geranylgeranyl Diphosphate |
Heteromer P53610; Q04631; | 50.0 | 1×ZN; 1×CL; 1×GRG; 1×GER; | |||
| Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method. | homo-6-mer | 95.86 | 6×GNP; 5×9RK; 1×PEG; 6×MG; 3×CIT; | |||
| Antibody derived (Abd-4) small molecule binding to KRAS. | homo-6-mer | 95.86 | 6×MG; 6×GNP; 3×D2Z; | |||
| KRAS-169 Q61H GPPNHP | homo-6-mer | 96.41 | 6×GNP; 6×MG; 3×CIT; | |||
| Antibody derived (Abd-8) small molecule binding to KRAS. | homo-6-mer | 95.83 | 6×MG; 6×GNP; 4×CVK; | |||
| Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method. | homo-6-mer | 95.83 | 6×GNP; 9×9R5; 1×PEG; 6×MG; 1×DMS; | |||
| KRAS G12V and peptide complex | homo-6-mer | 96.1 | 6×MG; 6×GDP; | |||
| Crystal structure of KRAS-G75A mutant, GDP-bound | homo-4-mer | 95.83 | 4×GDP; 4×MG; | |||
| Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12C | homo-3-mer | 93.86 | 2×SO4; 3×GDP; 2×21F; | |||
| Crystal Structure of small molecule vinylsulfonamide 8 covalently bound to K-Ras G12C | homo-3-mer | 94.41 | 3×GDP; 1×21C; | |||
| CRYSTAL STRUCTURE OF INACTIVE KRAS G12D (GDP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747 | homo-3-mer | 96.34 | 3×GDP; 3×MG; 2×R6W; | |||
| KRAS4B A146V 1-185 bound to GDP | homo-2-mer | 96.36 | 2×GDP; | |||
| Second-site screening of K-Ras in the presence of covalently attached first-site ligands | homo-2-mer | 94.67 | 2×GDP; 2×MG; 2×2XR; | |||
| Crystal Structure of small molecule disulfide 6 bound to K-Ras G12C | homo-2-mer | 94.05 | 4×CA; 2×20G; 2×GDP; | |||
| G13D mutant of KRAS4b (2-169) bound to GDP with the switch-I in fully open conformation | homo-2-mer | 99.41 | 2×GDP; | |||
| Crystal structure of KRAS A146T-GDP demonstrating open switch 1 conformation | homo-2-mer | 95.83 | 2×GDP; | |||
| Crystal Structure of small molecule disulfide 4 covalently bound to K-Ras G12C | homo-2-mer | 94.05 | 4×CA; 2×20H; 2×GDP; | |||
| CRYSTAL STRUCTURE OF CRYSTAL FORM 2 OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747 | homo-2-mer | 95.83 | 2×MG; 2×GCP; 1×R6W; | |||
| G13D mutant of KRAS4b (2-169) bound to GDP with the switch-I in fully open conformation crystallize… | homo-2-mer | 99.41 | 2×GDP; 2×NA; | |||
| Crystal structure of KRAS-G12D/G75A mutant, GDP-bound | homo-2-mer | 95.21 | 2×GDP; 2×MG; 1×NA; 2×CL; | |||
| Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 9b | homo-2-mer | 96.41 | 2×GCP; 2×MG; 1×JJQ; | |||
| Crystal Structure of KRAS-G12D in complex with GMP-PCP and compound 15R | homo-2-mer | 96.41 | 2×GCP; 2×MG; 1×JJN; | |||
| CRYSTAL STRUCTURE OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747 | homo-2-mer | 96.41 | 2×MG; 2×GCP; 1×R6W; | |||
| Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 15 | homo-2-mer | 96.41 | 2×GCP; 2×MG; 2×EDO; 1×JJN; | |||
| Crystal structure of small molecule aziridine 3 covalently bound to K-Ras G12C | homo-2-mer | 94.58 | 2×GDP; 6×CA; 2×8YA; 1×GOL; | |||
| CRYSTAL STRUCTURE OF ACTIVE KRAS G12D (GPPCP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747 | homo-2-mer | 96.41 | 1×R6W; 2×GCP; 2×MG; | |||
| Crystal Structure of K-Ras G12C (cysteine-light), GDP-bound | homo-2-mer | 94.19 | 4×MG; 2×GDP; | |||
| Solution structures of full-length K-RAS bound to GDP | monomer | 97.01 | ||||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang… | monomer | 96.32 | 1×GDP; 1×MG; 1×BZI; | |||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang… | monomer | 96.39 | 1×GSP; 1×MG; 1×BEN; 1×GOL; | |||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang… | monomer | 96.39 | 1×GCP; 2×MG; 2×EDO; | |||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang… | monomer | 96.39 | 1×9LI; 1×GCP; 2×MG; 1×GOL; 1×EDO; 1×DMS; 1×ACT; | |||
| KRAS4b K117N 1-185 bound to GNP-Mg2+ | monomer | 96.27 | 1×GNP; 1×MG; | |||
| KRAS4b WT 1-185 bound to GDP-Mg2+ | monomer | 97.01 | 1×MG; 1×GDP; 1×GOL; | |||
| Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method. | monomer | 96.39 | 2×MG; 1×GNP; 1×9R5; 1×GOL; 1×PEG; | |||
| Crystal structure analysis of human KRAS mutant | monomer | 96.39 | 1×GDP; | |||
| KRAS full length wild-type GPPNHP | monomer | 96.99 | 2×MG; 1×GNP; 1×GOL; | |||
| KRAS full length G12D GPPNHP | monomer | 96.39 | 2×MG; 1×GNP; | |||
| KRAS4b A146T 1-185 bound to GDP | monomer | 96.39 | 1×GDP; | |||
| Crystal Structure of WT KRAS4a with bound GDP and Mg ion | monomer | 100 | 1×GDP; 1×MG; | |||
| Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP8784 | monomer | 96.39 | 1×GDP; 1×MG; 1×IOD; | |||
| KRAS 1-169 G12C Mutant at 100k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRas | monomer | 95.86 | 1×GDP; 1×MG; | |||
| KRAS-G12D in complex with BI-2865 | monomer | 95.27 | 1×GDP; 1×MG; 4×EDO; 1×OFU; | |||
| Crystal structure of human KRAS at 1.12 A | monomer | 95.86 | 1×MG; 1×GDP; | |||
| Crystal Structure of a GDP-bound G12C Oncogenic Mutant of Human GTPase KRas | monomer | 95.86 | 1×GDP; 1×MG; | |||
| X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 17) | monomer | 94.08 | 1×GDP; 1×MG; 1×MZN; | |||
| Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution | monomer | 95.86 | 1×GNP; 4×MG; | |||
| Crystal structure of KRAS G12D in complex with GDP and compound 14 | monomer | 95.86 | 1×GDP; 1×MG; 1×VR5; | |||
| KRasG12C in complex with GDP and compound 2 | monomer | 93.98 | 1×MG; 1×H40; 1×GDP; | |||
| Second-site screening of K-Ras in the presence of covalently attached first-site ligands | monomer | 94.67 | 1×GDP; 1×MG; 1×2XE; | |||
| Crystal Structure of GDP-bound Human KRas | monomer | 96.45 | 1×GDP; 1×MG; | |||
| Crystal Structure of KRAS G12D with compound 15 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8… | monomer | 94.08 | 1×GDP; 1×MG; 2×7L8; | |||
| Crystal structure of KRAS G12D with compound 36 (4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8… | monomer | 94.08 | 1×GDP; 1×7OE; 1×MG; | |||
| KRasG12C ligand complex | monomer | 94.08 | 1×MG; 1×GDP; 1×MKZ; | |||
| Crystal structure of human KRAS in space group R32 | monomer | 95.27 | 1×MG; 1×GOL; 1×TRS; 1×PEG; 1×GDP; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation | monomer | 95.86 | 1×GDP; 1×MG; 1×0QX; | |||
| Crystal structure of KRAS G12D in complex with GDP and compound 5 | monomer | 95.86 | 1×GDP; 1×MG; 1×VM9; | |||
| KRasG12C ligand complex | monomer | 93.49 | 1×MG; 1×GDP; 1×O7K; 1×SO4; | |||
| Crystal Structure of small molecule ARS-1620 covalently bound to K-Ras G12C | monomer | 94.08 | 4×CA; 1×91S; 1×GOL; 1×GDP; | |||
| KRAS 1-169 G12C Mutant at 240k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| KRAS 1-169 G12C Mutant at 310k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| KRAS 1-169 G12C Mutant at 277k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| Second-site screening of K-Ras in the presence of covalently attached first-site ligands | monomer | 94.67 | 1×GDP; 1×MG; 1×2XO; | |||
| KRAS 1-169 G12C Mutant at 293k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| KRAS 1-169 G12C Mutant at 313k | monomer | 95.86 | 1×GDP; 1×MG; | |||
| Crystal structure of wild-type KRAS bound to GDP and Mg (Space group C2) | monomer | 96.45 | 1×GDP; 1×MG; | |||
| Crystal structure of compound 1 bound to K-Ras(G12D) | monomer | 94.08 | 1×GDP; 1×MG; 1×Y63; | |||
| Crystal structure of human KRAS with extended switch I loop | monomer | 95.21 | 1×GDP; 1×MG; 2×CL; | |||
| Crystal Structure of Small Molecule Disulfide 2C07 Bound to K-Ras Cys Light M72C GDP | monomer | 94.01 | 1×MG; 1×GDP; 1×92V; | |||
| GDP-bound KRAS P34R mutant | monomer | 96.13 | 1×GDP; 1×MG; | |||
| Crystal structure of KRAS G12D in complex with GDP and compound 8 | monomer | 95.86 | 1×GDP; 1×MG; 1×VQT; | |||
| Crystal structure of human KRAS G12C covalently bound with Araxes WO2020/028706A1 compound I-1 | monomer | 94.08 | 1×MG; 1×GDP; 1×U4L; | |||
| Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitor | monomer | 94.08 | 1×GDP; 2×CA; 1×OHY; | |||
| Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP10343 | monomer | 96.39 | 1×GDP; 1×MG; 3×SO4; | |||
| KRAS mutant-A59G in GDP-bound | monomer | 95.86 | 1×MG; 1×GDP; | |||
| Crystal Structure of KRAS G12D with compound 25 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8… | monomer | 94.08 | 1×GDP; 1×MG; 1×7NL; 1×GOL; 1×EDO; | |||
| Crystal structure of KRAS-K104Q mutant, GDP-bound | monomer | 95.86 | 1×GDP; 1×MG; 4×SO4; | |||
| Crystal Structure of KRasG13C in Complex with Nucleotide-based Covalent Inhibitor edaGDP | monomer | 94.08 | 1×VJ8; | |||
| Crystal structure of WT KRAS4a with bound GMPPNP and Mg ion | monomer | 100.0 | 1×GNP; 2×MG; | |||
| GDP-bound KRAS G12C in complex with YK-8S | monomer | 99.41 | 1×GDP; 1×MG; 1×DWI; | |||
| Crystal structure of K-Ras(G12D) GppNHp bound to cyclic peptide ligand KD2 | monomer | 93.98 | 1×GNP; 1×MG; | |||
| Crystal structure of human KRAS G12A mutant in complex with GTP | monomer | 94.94 | 1×GTP; 1×MG; | |||
| X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 3) | monomer | 94.08 | 1×GDP; 1×MG; 1×MZQ; | |||
| Crystal Structure of human KRAS G12C covalently bound to AMG 510 | monomer | 93.98 | 1×MG; 1×GDP; 1×MOV; | |||
| Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI739 | monomer | 94.08 | 1×MG; 1×GDP; 1×94F; 2×EDO; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation | monomer | 95.86 | 1×GDP; 1×MG; 1×0QV; | |||
| Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI484 | monomer | 94.08 | 1×MG; 1×GDP; 1×94C; 1×EDO; | |||
| Crystal structure of human KRAS G12A mutant in complex with GDP | monomer | 95.27 | 1×GDP; 1×MG; 1×PGE; 1×NA; | |||
| Crystal structure of small molecule acrylamide 1 covalently bound to K-Ras G12C | monomer | 94.08 | 1×GDP; 1×MG; 1×8YD; | |||
| Crystal Structure of KRasG13C in Complex with Nucleotide-based covalent Inhibitor bdaGDP | monomer | 94.08 | 1×VJB; | |||
| Second-site screening of K-Ras in the presence of covalently attached first-site ligands | monomer | 94.67 | 1×GDP; 1×MG; 1×2XG; | |||
| Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12C | monomer | 94.08 | 1×GDP; 1×MG; 1×K9J; | |||
| Crystal Structure of small molecule alpha,beta-ketoamide 4 covalently bound to K-Ras(G12R) | monomer | 94.08 | 1×MG; 1×P7U; 1×GDP; | |||
| Crystal Structure of compound 10 covalently bound to K-Ras G12C | monomer | 93.94 | 1×GDP; 1×MG; 1×BQD; 2×GOL; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation | monomer | 95.27 | 1×GDP; 1×MG; 1×0QR; | |||
| Crystal structure of human WT-KRAS in complex with GDP | monomer | 95.86 | 1×GDP; 1×MG; | |||
| Crystal structure of human KRAS Q61A mutant in complex with GDP | monomer | 95.18 | 1×GDP; 1×MG; | |||
| KRas G12C in complex with Compound 5c | monomer | 95.15 | 1×GDP; 1×MG; 1×IQC; | |||
| KRas G12C in complex with Compound 7b | monomer | 95.27 | 1×GDP; 1×MG; 1×SO4; 1×IQN; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation | monomer | 95.27 | 1×GDP; 1×MG; 1×0QY; | |||
| Crystal structure of human KRAS G12D mutant in complex with GDP | monomer | 95.73 | 1×GDP; 1×MG; 1×GOL; | |||
| KRasG12C in complex with inhibitor | monomer | 95.12 | 1×GDP; 1×MG; 1×Y9D; | |||
| Crystal structure of human KRAS G12A mutant in complex with GTP-gamma-S | monomer | 94.9 | 1×MG; 1×GSP; | |||
| Crystal Structure of a G12C Oncogenic Variant of Human KRas Bound to a Novel GDP Competitive Covale… | monomer | 95.86 | 1×MG; 1×Y9Z; | |||
| Structure of Kras in complex with inhibitor MK-1084 | monomer | 93.94 | 1×GDP; 1×MG; 1×A1H5U; | |||
| Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the… | monomer | 94.08 | 1×GDP; 1×MG; 1×M1X; | |||
| Crystal structure of human KRAS G12A mutant in complex with GppNHp | monomer | 94.84 | 1×MG; 1×9GM; | |||
| Crystal structure of human KRAS A59G mutant in complex with GCP | monomer | 95.86 | 1×GCP; | |||
| Antibody derived (Abd-7) small molecule binding to KRAS. | monomer | 95.86 | 1×MG; 1×GNP; 1×D1W; | |||
| Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the… | monomer | 94.08 | 1×GDP; 1×MG; 1×QH4; | |||
| KRAS G12D in complex with Compound 5B (7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(2S)-1-methylpyrrol… | monomer | 94.08 | 1×GDP; 1×MG; 1×7IZ; 1×GOL; | |||
| GDP-bound KRAS G12D in complex with YK-8S | monomer | 99.41 | 1×GDP; 1×MG; 1×DNU; | |||
| Crystal structure of GDP-bound T50I mutant of human KRAS4B | monomer | 95.86 | 1×GDP; 1×MG; | |||
| Structural basis of impaired hydrolysis in KRAS Q61H mutant | monomer | 95.81 | 1×GTP; 1×MG; | |||
| Crystal structure of human KRAS G12A mutant in complex with GDP (EDTA soaked) | monomer | 95.0 | 1×MG; 1×GDP; | |||
| The haddock model of GDP KRas in complex with promazine using chemical shift perturbations and inte… | monomer | 96.45 | 1×GDP; 1×MG; 1×P2Z; | |||
| The haddock model of GDP KRas in complex with promethazine using NMR chemical shift perturbations | monomer | 96.45 | 1×GDP; 1×MG; 1×ZM7; | |||
| The HADDOCK structure model of GDP KRas in complex with its allosteric inhibitor E22 | monomer | 96.45 | 1×GDP; 1×MG; 1×QPD; | |||
| KRAS G12D in complex with MRTX-1133 | monomer | 94.05 | 1×GDP; 1×6IC; 1×MG; | |||
| Crystal Structure of small molecule ARS-917 covalently bound to K-Ras G12C | monomer | 94.05 | 2×CA; 1×8ZG; 1×GOL; 1×GDP; | |||
| Crystal structure of wild-type KRAS (1-169) bound to GDP and Mg (Space group P3) | monomer | 96.43 | 3×MG; 1×GDP; 1×GOL; | |||
| Crystal Structure of small molecule vinylsulfonamide 15 covalently bound to K-Ras G12C | monomer | 93.83 | 1×GDP; | |||
| Crystal structure of human KRAS G12V mutant in complex with GDP | monomer | 95.83 | 1×MG; 1×GDP; | |||
| Structure of Mg-free KRAS4b (2-169) bound to GDP with the switch-I in fully open conformation | monomer | 96.43 | 1×GDP; | |||
| Crystal structure of KRAS4a-R151G with bound GDP and Mg ion | monomer | 99.41 | 1×GDP; 1×MG; | |||
| Crystal structure of GMPPNP-bound G12R mutant of human KRAS4b | monomer | 95.78 | 1×MG; 1×GNP; | |||
| Crystal Structure of KRAS G12D with compound 24 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8… | monomer | 94.05 | 1×GDP; 1×7NZ; 1×MG; | |||
| KRAS-G13D-GDP in complex with Cpd36 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-… | monomer | 95.83 | 1×MG; 1×GDP; 1×XV3; | |||
| Crystal Structure of small molecule vinylsulfonamide covalently bound to K-Ras G12C | monomer | 93.75 | 1×MG; 1×21R; 1×GDP; | |||
| KRAS full length G12V GPPNHP | monomer | 95.71 | 1×MG; 1×GNP; | |||
| Crystal structure of KRAS V14I-GDP demonstrating disorder switch 1 conformation - Form 2 | monomer | 95.65 | 1×GDP; | |||
| KRasG12C in complex with GDP and JDQ443 | monomer | 94.05 | 2×MG; 1×H2T; 1×GDP; | |||
| KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 9 | monomer | 94.05 | 2×MG; 1×NZX; 1×GDP; | |||
| Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor | monomer | 93.9 | 2×CA; 1×GDP; 1×O5S; | |||
| Crystal structure of KRAS-G12C (GDP-bound) in complex with BBO-8520 | monomer | 95.24 | 1×GDP; 1×MG; 1×Y8N; | |||
| Discovery of a KRAS G12V Inhibitor in vivo Tool Compound starting from an HSQC-NMR based Fragment H… | monomer | 94.64 | 1×2XO; 1×GDP; 1×MG; 1×LX6; | |||
| Crystal Structure of small molecule vinylsulfonamide 14 covalently bound to K-Ras G12C | monomer | 93.86 | 1×GDP; | |||
| Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12C | monomer | 94.05 | 1×GDP; 1×MG; 1×K9M; | |||
| Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76 | monomer | 94.05 | 1×MG; 1×GDP; 1×U4U; | |||
| Crystal structure of KRAS-G12D/K104Q mutant, GDP-bound | monomer | 95.24 | 1×GDP; 1×MG; | |||
| Crystal Structure of human KRAS G12D mutant in complex with GDPNP | monomer | 95.76 | 1×MG; 1×GNP; | |||
| KRasG12C in complex with GDP and compound 3 | monomer | 94.05 | 2×MG; 1×H0O; 1×GDP; | |||
| Crystal structure of human WT-KRAS in complex with GTP | monomer | 95.48 | 1×GTP; 1×MG; | |||
| GDP-bound KRAS G12D in complex with TH-Z835 | monomer | 95.83 | 1×MG; 1×GDP; 1×05I; | |||
| Crystal structure of human WT-KRAS in complex with GTP-gamma-S | monomer | 95.45 | 1×GSP; 1×MG; | |||
| Crystal Structure of small molecule acrylamide 16 covalently bound to K-Ras G12C | monomer | 93.75 | 1×MG; 1×GDP; | |||
| Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor. | monomer | 94.05 | 2×CA; 1×GDP; 1×O67; | |||
| Crystal structure of active KRAS-G12C (GMPPNP-bound) in complex with BBO-8520 | monomer | 95.24 | 1×GNP; 1×MG; 1×Y8N; | |||
| GDP-bound KRAS G12D in complex with TH-Z816 | monomer | 95.83 | 1×MG; 1×05C; 1×GDP; | |||
| Crystal structure of KRAS G12C in complex with GNE-1952 | monomer | 94.05 | 1×MKZ; 1×GDP; 1×MG; | |||
| KRAS P34R mutant structure in complex with GTP analogue | monomer | 95.65 | 1×GNP; 1×MG; | |||
| Crystal structure of human KRAS G12C covalently bound with Taiho WO2020/085493A1 compound 6 | monomer | 94.05 | 1×MG; 1×GDP; 1×U50; 1×SO4; | |||
| GDP-bound KRAS G12D in complex with TH-Z827 | monomer | 95.83 | 1×MG; 1×GDP; 1×05F; | |||
| Crystal structure of human WT-KRAS in complex with GDP (EDTA soaked) | monomer | 95.48 | 1×GDP; 1×MG; | |||
| Crystal structure of wild-type KRAS4b(1-169) in complex with GMPPNP and Mg ion | monomer | 96.25 | 1×GNP; 1×MG; | |||
| NMR2 Structure of KRAS G12V (GMPPNP bound) in complex with (2E)-3-(1H-indol-2-yl)prop-2-enoic acid | monomer | 95.24 | 1×Z5I; | |||
| Crystal structure of N-acetylated KRAS (2-169) bound to GDP and Mg | monomer | 96.41 | 1×MG; 1×GDP; 1×ACE; | |||
| Crystal Structure of a GDP-bound G13D Oncogenic Mutant of Human GTPase KRas | monomer | 96.41 | 1×GDP; 1×MG; | |||
| Kras G12D in complex with compound 3 | monomer | 96.41 | 1×GCP; 1×YLE; 1×MG; | |||
| KRasG12C ligand complex | monomer | 94.61 | 1×V4T; 1×MG; 1×GDP; 1×CA; | |||
| Crystal Structure of small molecule ARS-107 covalently bound to K-Ras G12C | monomer | 94.61 | 2×CA; 1×C8G; 1×GDP; | |||
| Kras G12D in complex with compound 4 | monomer | 96.41 | 1×GCP; 1×MG; | |||
| KRAS G12D Mutant in complex with GMPPCP and cyclic peptide MP-9903 | monomer | 96.41 | 1×GCP; 1×MG; | |||
| Crystal structure of KRAS-G12D bound to GDP with switch 1 open conformation | monomer | 95.81 | 1×GDP; 1×MG; | |||
| Crystal Structure of small molecule ARS-853 covalently bound to K-Ras G12C | monomer | 94.61 | 1×MG; 2×GOL; 1×5UT; 1×GLY; 1×GDP; | |||
| Crystal Structure of KRAS-G12D in complex with GMP-PCP | monomer | 96.41 | 1×GCP; 1×MG; | |||
| Crystal Structure of a GDP-bound G12V Oncogenic Mutant of Human GTPase KRas | monomer | 96.41 | 1×GDP; 1×MG; | |||
| CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 15 | monomer | 95.71 | 1×GCP; 1×MG; 1×F0N; | |||
| Crystal structure of KRAS V14I-GDP demonstrating open switch 1 conformation - Form 1 | monomer | 95.81 | 1×GDP; | |||
| Crystal Structure of K-Ras G12C, GDP-bound | monomer | 96.18 | 1×GDP; 1×MG; 1×NA; | |||
| Crystal Structure of small molecule vinylsulfonamide 13 covalently bound to K-Ras G12C | monomer | 94.41 | 1×GDP; | |||
| KRAS G12C inhibitor | monomer | 96.41 | 1×GDP; 1×MG; 1×91G; | |||
| Crystal Structure of small molecule vinylsulfonamide 7 covalently bound to K-Ras G12C | monomer | 94.41 | 1×GDP; | |||
| Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor | monomer | 94.38 | 1×MG; 1×GDP; 1×OJ1; | |||
| KRAS-169 Q61H GPPNHP + PPIN-1 | monomer | 96.41 | 1×GNP; 1×MG; 2×CIT; 1×F6E; | |||
| CRYSTAL STRUCTURE OF KRAS-G12D(C118S) IN COMPLEX WITH BI-2852 AND GDP | monomer | 95.71 | 1×MG; 1×GDP; 1×F0K; 1×SO4; | |||
| CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH BI 2852 | monomer | 96.41 | 1×F0K; 1×MG; 1×GCP; | |||
| KRAS-169 Q61H GPPNHP + PPIN-2 | monomer | 96.41 | 1×GNP; 1×MG; 2×CIT; | |||
| KRasG12C ligand complex | monomer | 94.61 | 2×MG; 1×GDP; 1×PQI; | |||
| CRYSTAL STRUCTURE OF KRAS-G12D IN COMPLEX WITH COMPOUND 13 AND GCP | monomer | 96.41 | 1×GCP; 1×MG; | |||
| Crystal structure of GDP-bound KRAS with ten residues long internal tandem duplication in the switc… | monomer | 96.27 | 1×GDP; 1×MG; 5×SO4; | |||
| CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 18 | monomer | 96.32 | 1×MG; 1×NO3; 1×GCP; 1×EZZ; | |||
| KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 16 | monomer | 94.61 | 1×MG; 1×NZ6; 1×GDP; | |||
| Antibody derived (Abd-6) small molecule binding to KRAS. | monomer | 96.41 | 1×MG; 1×GNP; 1×D1Z; | |||
| Crystal structure of human KRAS P34R mutant in complex with GNP and Phosphate | monomer | 96.41 | 1×GNP; 1×MG; 1×PO4; | |||
| Crystal Structure of small molecule acrylamide 11 covalently bound to K-Ras G12C | monomer | 94.34 | 1×GDP; | |||
| KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) binder | monomer | 96.41 | 1×GDP; 1×MG; 1×91D; | |||
| Crystal Structure of a GDP-bound Q61L Oncogenic Mutant of Human GT- Pase KRas | monomer | 96.8 | 1×GDP; 1×MG; | |||
| Crystal structure of human KRAS P34R mutant in complex with GNP | monomer | 96.41 | 1×MG; 1×PO4; 1×GNP; | |||
| KRASG12C GDP form in complex with Cpd4 | monomer | 96.41 | 1×GDP; 1×QY5; | |||
| KRAS-169 Q61H GPPNHP + CH-2 | monomer | 96.41 | 1×MG; 1×GNP; 1×F8K; | |||
| KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) binder | monomer | 96.41 | 1×GDP; 1×MG; 1×8ZG; | |||
| Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the… | monomer | 94.61 | 1×GDP; 1×MG; 1×M1R; | |||
| Human K-Ras (Q61H) in complex with a GTP analogue | monomer | 96.41 | 1×MG; 1×GNP; 1×UNX; | |||
| MgGDP bound KRAS G12V | monomer | 96.41 | 1×MG; 1×GDP; | |||
| KRAS mutant-D33E in GDP-bound | monomer | 96.41 | 1×GDP; 1×MG; | |||
| Antibody derived (Abd-5) small molecule binding to KRAS. | monomer | 96.41 | 1×MG; 1×GNP; 1×D2W; | |||
| Covalent GTP-competitive inhibitors of KRAS G12C: Guanosine bisphosphonate Analogs | monomer | 96.2 | 1×6ZD; | |||
| KRAS-169 Q61H GPPNHP + CH-3 | monomer | 96.41 | 1×MG; 1×GNP; 1×F8Q; | |||
| KRAS-169 Q61H GPPNHP + CH-1 | monomer | 96.41 | 1×MG; 1×GNP; 1×F8T; | |||
| NMR2 Structure of KRAS G12V (GMPPNP bound) in complex with 5-(1H-indol-2-l)piperazin-2-one | monomer | 95.81 | 1×YVW; | |||
| Second-site screening of K-Ras in the presence of covalently attached first-site ligands | monomer | 95.78 | 1×GDP; 1×MG; 1×2XH; | |||
| KRAS-G13D-GDP in complex with Cpd38 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-… | monomer | 96.39 | 2×GOL; 1×GDP; 1×MG; 1×XQ6; | |||
| Crystal Structure of K-Ras WT, GDP-bound | monomer | 97.44 | 1×GDP; 1×CA; 1×NA; | |||
| CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 22 | monomer | 96.99 | 1×MG; 1×GCP; 1×F0B; | |||
| KRASG12C GDP form in complex with Cpd3 | monomer | 96.99 | 1×GDP; 1×MG; 1×PO4; 2×QWK; | |||
| Crystal structure of Mg-free KRAS-G12D bound to GDP | monomer | 96.32 | 1×GDP; | |||
| Wild-type K-Ras(GCP) pH 6.5 | monomer | 97.56 | 1×GDP; 1×MG; 2×GOL; | |||
| Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12C, alternative … | monomer | 94.58 | 1×MG; 1×21F; 1×GDP; | |||
| KRAS G13D bound to GDP (K13GDP) | monomer | 96.99 | 1×GDP; 1×CA; 1×NA; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation | monomer | 96.99 | 1×GDP; 1×MG; 1×0QW; | |||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation. | monomer | 96.39 | 1×GDP; 1×MG; | |||
| KRAS-G13D-GDP in complex with Cpd5 (1-((S)-10-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-11… | monomer | 96.39 | 1×XOI; 1×GDP; 3×CL; 1×MG; | |||
| Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor. | monomer | 94.58 | 3×CA; 1×GDP; 1×O5V; | |||
| Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor. | monomer | 95.18 | 1×MG; 1×GDP; 1×O5Y; | |||
| KRAS G13D bound to GppNHp (K13GNP) | monomer | 96.75 | 1×GNP; 1×MG; | |||
| Crystal structure of Mg-free wild-type KRAS (2-166) bound to GMPPNP in the state 1 conformation | monomer | 97.58 | 1×NA; 1×EDO; 1×GNP; | |||
| Crystal structure of KRas G12V/D38P, bound to GDP | monomer | 96.97 | 1×GDP; | |||
| KRAS-G13D in complex with BI-2493 | monomer | 97.56 | 1×GDP; 1×MG; 2×EDO; 1×VU6; | |||
| KRAS-G12V in complex with BI-2865 | monomer | 97.56 | 1×GDP; 1×MG; 2×EDO; 1×OFU; | |||
| KRAS-G12C in complex with BI-2865 | monomer | 97.56 | 1×GDP; 1×MG; 2×EDO; 1×OFU; | |||
| KRAS-G13D in complex with BI-2865 | monomer | 97.56 | 1×GDP; 1×MG; 3×EDO; 1×OFU; | |||
| KRAS in complex with BI-2865 | monomer | 98.17 | 1×GDP; 1×MG; 2×EDO; 1×OFU; | |||
| KRasG12C ligand complex | monomer | 96.95 | 1×MG; 1×GDP; 1×PUO; | |||
| KRAS G12D (GppCp) with MRTX-1133 | monomer | 96.34 | 1×6IC; 1×GCP; 1×GDP; 1×GOL; 1×ACT; 1×MG; | |||
| KRASG12C GDP form in complex with Cpd1 | monomer | 98.17 | 1×GDP; 1×MG; 1×QWB; | |||
| KRasG12C ligand complex | monomer | 96.34 | 1×MG; 1×GDP; 1×VLE; | |||
| Crystal structure of oncogenic KRAS Q61E GMPPCP-bound | monomer | 97.56 | 1×GCP; 1×MG; | |||
| KRAS-G12C in Complex with Compound 1 | monomer | 97.56 | 1×GDP; 2×MG; 1×WYU; | |||
| KRAS in complex with precursor 1 | monomer | 98.17 | 1×GDP; 1×MG; 1×EDO; 1×LR4; | |||
| CRYSTAL STRUCTURE OF BIT-BLOCKED KRAS-G12V-S39C IN COMPLEX WITH COMPOUND 20a | monomer | 96.95 | 1×GDP; 1×2XO; 1×MG; 1×LXU; | |||
| Crystal Structure of K-Ras(G12S) | monomer | 98.17 | 1×GDP; 1×MG; | |||
| Crystal Structure of small molecule beta-lactone 5 covalently bound to K-Ras(G12S) | monomer | 96.34 | 1×GDP; 1×I7H; 1×MG; | |||
| Crystal Structure of small molecule beta-lactone 1 covalently bound to K-Ras(G12S) | monomer | 96.34 | 1×MG; 1×I6T; 1×GDP; 1×SO4; | |||
| KRASG12C GDP form in complex with Cpd2 | monomer | 98.15 | 1×QWH; 1×GDP; 1×MG; 1×SO4; | |||
| CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12 | monomer | 97.56 | 1×GDP; 1×MG; 1×LXK; 1×SO4; | |||
| CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 23 (BI-0474) | monomer | 97.55 | 1×GDP; 1×MG; 1×LXD; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4dso.1.A | monomer | 0.85 | 88.77 | |||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 4dso.1.A | monomer | 0.85 | 99.47 | |||